2.30p+0.00 (+0.00%)26 Feb 2024, 14:40
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Cizzle Biotechnology Holdings PLC Fundamentals

Company NameCizzle Biotechnology Holdings PLCLast Updated2024-02-26
Shares in Issue363.842 mMarket Cap£8.37 m
PE Ratio2.28Dividend per Share0
Dividend Yield0Dividend Cover0
EPS£-0.00EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio1.0495Cash Equity Ratio0.1719
Quick Ratio5.1846Current Ratio5.18
Price To Book Value3.1888ROCE0

Cizzle Biotechnology Holdings PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Cizzle Biotechnology Holdings PLC Company Financials

Tangible Assets00
Intangible Assets£2.08 m£200,000.00
Total Fixed Assets£2.08 m£200,000.00
Cash & Equivalents£478,000.00£875,000.00
Other Assets00
Total Assets£2.79 m£1.16 m
Creditors within 1 year£145,000.00£218,000.00
Creditors after 1 year00
Other Liabilities00
Total Liabilities£145,000.00£218,000.00
Net assets£2.64 m£937,000.00
Called up share capital£35,000.00£26,000.00
Share Premium£34.92 m£32.57 m
Profit / Loss-£963,000.00-£3.96 m
Other Equity£2.64 m£937,000.00
Preference & Minorities00
Total Capital Employed£2.64 m£937,000.00
Debt Ratio00
Assets / Equity1.04951.0495
Cash / Equity0.17190.1719
Cash Flow20222021
Cash from operating activities-£872,000.00-£1.01 m
Cashflow before financing-£277,000.00£1.02 m
Increase in Cash-£397,000.00£868,000.00
Cost of sales00
Gross Profit00
Operating Profit-£963,000.00-£3.96 m
Pre-Tax profit-£963,000.00-£3.96 m

Cizzle Biotechnology Holdings PLC Company Background

ActivitiesCizzle Biotechnology Holdings PLC is in the early stages of developing a blood test for the early detection of a majority of the different forms of lung cancer. Its proof-of-concept prototype test is based on the ability to detect a stableplasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is highly correlated with early stage lung cancer.
Latest Interim Date28 Sep 2023
Latest Fiscal Year End Date27 Apr 2023

Cizzle Biotechnology Holdings PLC Directors

2011-08-09Mr. John Corelli James ThynneNon-Executive Director
2011-08-09Mr. Gareth JonesExecutive Director,Chief Technology Officer
2019-04-30Mr. Jonathan David Freeman Non-Executive Director,Chairman
2011-08-09Mr. Simon John Gibson OBENon-Executive Director
2016-05-31Dr. Andrew William Nelson OBENon-Executive Director
2011-08-09Mr. Owen Griffith Ronald JonesNon-Executive Director
2011-08-09Mr. Giles Alexander DaviesExecutive Director,Chief Financial Officer and Co Secretary
2012-06-27Mr. Ceri JonesExecutive Director,Chief Financial Officer and Company Sec
2023-05-01Dr. Allan John SymsExecutive Director,Chairman
2011-08-09Mr. Shaun Piers OxenhamExecutive Director,Chairman
2019-07-04Dr. James Stuart MckenzieExecutive Director,Chief Executive Officer
2019-07-04Dr. Majid ZoorobExecutive Director,Chief Technical Officer
2015-11-20Mr. Russell Anthony BanksExecutive Director,Chief Financial Officer
2016-06-23Mr. Philip Antony MarshallNon-Executive Director
2023-05-01Mr. John Michael TreacyNon-Executive Director
2023-05-01Mr. Dawn Alison CoverleyNon-Executive Director
2023-05-01Mr. Nigel Ronald LeeExecutive Director,Finance Director

Cizzle Biotechnology Holdings PLC Contact Details

Company NameCizzle Biotechnology Holdings PLC
AddressHeslington Hall, Heslington, York, YO10 5DD
Telephone+44 207264444

Cizzle Biotechnology Holdings PLC Advisors

StockbrokerPeterhouse Corporate Finance Ltd
Phone+44 2074690930
Fax+44 2072209798
Nominated AdviserNorthland Capital Partners
Phone+44 2038616625
Fax+44 2076005975
StockbrokerNorthland Capital Partners
Phone+44 2038616625
Fax+44 2076005975
SolicitorGreenaway Scott LLP
Phone029 2009 5500
RegistrarLink Asset Services
Phone+44 8716640300
Fax+44 2086392342
Financial PR AdviserInstinctif Partners
Phone+44 2074572020
BankBarclays Bank PLC